# TL011 in Severe, Active Rheumatoid Arthritis Patients

> **NCT01123070** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceutical Industries, Ltd.** · enrollment: 54 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** TL011, anti CD20, for the treatment of rheumatoid arthritis
- **BIOLOGICAL:** MabThera infusions

## Key facts

- **NCT ID:** NCT01123070
- **Lead sponsor:** Teva Pharmaceutical Industries, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-05
- **Primary completion:** 2012-04-23
- **Final completion:** 2012-04-23
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2021-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01123070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01123070, "TL011 in Severe, Active Rheumatoid Arthritis Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01123070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*